Panoptosis In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
PANoptosis is a unique programmed cell death pathway that involves pyroptosis, apoptosis, and necroptosis simultaneously. Unlike traditional apoptosis or pyroptosis alone, PANoptosis is driven by the PANoptosome complex, which activates caspase-1, caspase-8, and MLKL in a coordinated manner. In neurodegenerative diseases, PANoptosis contributes to neuronal loss through multiple cell death pathways, amplifying neuroinflammation and accelerating disease progression. This pathway page examines the molecular components of PANoptosis and its role in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease.
| Component |
Type |
Function |
Neurodegenerative Role |
| NLRP3 |
Sensor |
Inflammasome activation |
Neuroinflammation |
| ASC |
Adaptor |
Protein recruitment |
Caspase-1 activation |
| caspase-1 |
Protease |
Pro-inflammatory cell death |
Pyroptosis initiation |
| caspase-8 |
Protease |
Extrinsic apoptosis |
Apoptosis initiation |
| caspase-3 |
Protease |
Executioner caspase |
Apoptosis execution |
| MLKL |
Pseudokinase |
Necroptosis execution |
Membrane permeabilization |
| ZBP1 |
Sensor |
Viral/stress sensing |
PANoptosome assembly |
The PANoptosome is a multiprotein signaling platform that coordinates PANoptosis:
- NLRP3-PANoptosome: NLRP3 recruits ASC, caspase-1, caspase-8
- ZBP1-PANoptosome: ZBP1 senses nucleic acids, activates PANoptosis
- AIM2-PANoptosome: AIM2 detects cytosolic DNA
flowchart TD
A[Neuropathological Stress] --> B[ZBP1/NLRP3/AIM2 activation]
B --> C[PANoptosome assembly]
C --> D[ caspase-1 activation]
C --> E[ caspase-8 activation]
C --> F[MLKL activation]
D --> G[Pyroptosis<br/>/ gasdermin D cleavage]
E --> H[Apoptosis<br/>/ caspase-3 activation]
F --> I[Necroptosis<br/>/ membrane disruption]
G --> J[Inflammatory cell death<br/>/ DAMPs release]
H --> J
I --> J
J --> K[Neuronal loss<br/>/ Neuroinflammation]
- Aβ triggers PANoptosome: Aβ oligomers activate NLRP3 inflammasome and ZBP1
- Caspase cascade: Aβ activates caspase-1, caspase-8, and caspase-3
- Gasdermin D involvement: GSDMD cleavage drives pyroptotic cell death
- MLKL activation: Aβ-induced necroptosis contributes to neuronal loss
- Pathological tau: Hyperphosphorylated tau triggers PANoptosome assembly
- Synaptic loss: PANoptosis contributes to synaptic dysfunction
- Microglial activation: PANoptosis in microglia amplifies neuroinflammation
| Target |
Approach |
Mechanism |
| NLRP3 inhibitors |
MCC950 |
Block PANoptosome |
| caspase-1 inhibitors |
VX-765 |
Prevent pyroptosis |
| caspase-8 inhibitors |
Z-IETD-FMK |
Block extrinsic apoptosis |
| MLKL inhibitors |
Necrosulfonamide |
Prevent necroptosis |
- α-Synuclein: PFFs trigger PANoptosis in dopaminergic neurons
- Mitochondrial stress: PINK1/Parkin dysfunction sensitizes neurons to PANoptosis
- Inflammasome activation: NLRP3 activation in PD brain
¶ LRRK2 and PANoptosis
- LRRK2 mutations: G2019S enhances PANoptosis susceptibility
- Kinase activity: LRRK2 inhibitors reduce PANoptotic cell death
- TDP-43 aggregates: Trigger PANoptosome formation
- Loss of nuclear TDP-43: Sensitizes motor neurons to PANoptosis
- DPR proteins: Poly-GR/Poly-GA induce PANoptosis
- Stress granules: Persistent granules trigger ZBP1 activation
- mHTT aggregates: Activate NLRP3 inflammasome
- Transcriptional dysregulation: Affect PANoptosis regulators
- Energy failure: AMPK activation promotes PANoptosis
| Biomarker |
Detection |
Disease Relevance |
| GSDMD |
CSF, blood |
Cell death marker |
| cleaved caspase-1 |
Tissue |
Pyroptosis activity |
| p-MLKL |
Blood, tissue |
Necroptosis activity |
| IL-1β/IL-18 |
CSF, blood |
Inflammasome activation |
| PANoptosis-related gene signature |
RNA-seq |
Diagnostic potential |
- NLRP3 inhibitors: MCC950, Dapansutrile
- caspase-1 inhibitors: VX-765, Ac-YVAD-cmk
- caspase-8 inhibitors: Z-IETD-FMK
- MLKL inhibitors: Necrosulfonamide
- Curcumin: Modulates NLRP3
- Resveratrol: Sirtuin-mediated PANoptosis regulation
- Sulforaphane: Nrf2 activation, anti-PANoptosis
- CRISPR-Cas9: Target PANoptosis genes
- RNAi: Knockdown of key regulators
¶ Research Landscape
Key findings advancing PANoptosis understanding:
- Christgen et al. (2020): Defined PANoptosis as distinct cell death type
- Kuang et al. (2020): ZBP1 drives PANoptosis in neurodegeneration
- Liu et al. (2023): PANoptosis in AD pathogenesis
- Yuan et al. (2023): Therapeutic targeting of PANoptosis
PANoptosis represents a critical pathway at the intersection of multiple cell death modalities in neurodegeneration. The coordinated activation of pyroptotic, apoptotic, and necroptotic machinery contributes significantly to neuronal loss across AD, PD, ALS, and HD. Understanding the molecular triggers and signaling cascades driving PANoptosis offers novel therapeutic opportunities for neuroprotective interventions. Targeting the PANoptosome complex or its downstream effectors may provide more comprehensive neuroprotection than targeting individual cell death pathways.
The study of Panoptosis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Christgen et al. Identification of the PANoptosome, a molecular platform for pyroptosis, apoptosis, and necroptosis. J Cell Biol, 2020
- Kuang et al. ZBP1-mediated PANoptosis in neurodegeneration. Nat Neurosci, 2020
- Liu et al. PANoptosis in Alzheimer's disease: molecular mechanisms and therapeutic implications. Front Aging Neurosci, 2023
- Yuan et al. Targeting PANoptosis for neurodegenerative diseases. Trends Pharmacol Sci, 2023
- Wang et al. PANoptosis in Parkinson's disease. Mol Neurodegener, 2023
- Lee et al. NLRP3 inflammasome and PANoptosis in ALS. Acta Neuropathol, 2022
- Zhang et al. PANoptosis in Huntington's disease. Cell Death Dis, 2023
- Zhou et al. Gasdermin inhibitors in neuroprotection. Cell Mol Neurobiol, 2023
- Gulbins et al. Targeting PANoptosis in disease. Nat Rev Drug Discov, 2023
- Jiang et al. Biomarkers of PANoptosis in neurodegenerative diseases. Adv Sci, 2024
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
10 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 31%